皮下Casirivimab和Imdevimab抗体组合与安慰剂对早期无症状SARS-CoV-2感染症状的发展的影响:随机临床试验
Meagan P O'Brien1, Eduardo Forleo-Neto1, Neena Sarkar1
1Regeneron Pharmaceuticals Inc, Tarrytown, New York.
JAMA
|January 14, 2022
概括
皮下用卡西里维玛和伊姆迪维玛治疗显著降低了无症状个体的COVID-19进展. 这种早期干预也减少了症状持续时间和病毒载量.
科学领域:
- 传染性疾病
- 病毒学
- 临床试验
背景情况:
- 早期使用抗SARS-CoV-2治疗可以预防COVID-19的症状.
- 鉴定无症状感染的有效治疗方法对于公共卫生至关重要.
研究的目的:
- 评估结合性皮下注射卡西里维玛和伊梅迪维玛在预防COVID-19症状进展方面的有效性.
- 评估这种治疗对症状持续时间和病毒载量的影响.
主要方法:
- 一个随机的,双盲的,安慰剂控制的第三阶段试验.
- 在接触后96小时内涉及无症状的SARS-CoV-2 RT-qPCR阳性个体.
- 参与者接受了 1200 毫克皮下卡西里维玛和伊德维玛或安慰剂.
主要成果:
- 卡西里维玛和伊姆迪维玛显著降低了COVID-19的症状发展 (29. 0%与42. 3%相比).
- 治疗减少了每位参与者的症状周约5. 6天.
- 它还减少了高病毒载量周,并且具有与安慰剂相比的安全性.
结论:
- 在早期无症状的SARS-CoV-2感染中,皮下注射的casirivimab和imdevimab有效预防症状性COVID-19.
- 这种治疗为管理早期感染和减少传播潜力提供了有价值的选择.
相关概念视频
Clinical Trials
9.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
9.5K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
282
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
282


